Bristol-Myers Squibb Company (BMY) stock price, chart and research
Bristol-Myers Squibb Company (BMY) last traded at $62.14 at the close on November 9, 2026, up $0.00 (0.00%) on the day. In after-hours trading it was $62.43.
- Day range: $61.80 to $63.06
- 52-week range: $45.27 to $68.64
- Market cap: $127.02 billion
- P/E (trailing 12 months): 13.78
- Forward P/E: 9.28
- EPS (trailing 12 months): $4.51
- Dividend yield: 4.06%
- Volume: 7,667,518 shares
About Bristol-Myers Squibb Company
Sector: Healthcare; industry: Drug Manufacturers - General; headquarters: United States; CEO: Dr. Christopher S. Boerner Ph.D.; 32,500 employees; listed since 1972-06-01.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment…
Financials
Revenue over the last 12 months was $50.03 billion, net income $9.24 billion, a profit margin of 18.5%. Revenue grew 4.2% from a year earlier.
Institutional owners of BMY (13F)
Tracked managers holding BMY in 13F filings for the quarter ending 2026-09-30:
- Dimensional Fund Advisors LP: $1.25 billion, 0.23% of its portfolio (added)
- Simplex Trading, LLC: $10.4 million, 0.33% of its portfolio (added)
- IMC-Chicago, LLC: $9.9 million, 0.09% of its portfolio (added)
- Wolverine Asset Management LLC: $227,000.00, 0.01% of its portfolio (new)
ETFs that hold BMY
- SPY: SPDR S&P 500 ETF
- XLV: Health Care Select Sector SPDR
- VOO: Vanguard S&P 500 ETF
- IVV: iShares Core S&P 500 ETF
- VTI: Vanguard Total Stock Market
- ITOT: iShares Core S&P Total US
Research BMY with LunaTerminal
- Interactive chart from one day to ten years, with volume, technicals and comparisons.
- Valuation, analyst ratings, dividends, earnings history and recent news.
- Ask LunaTerminal about BMY: AI answers that cite dated data; no account needed for 5 prompts
- 13F filings: which managers own what
- How advisors use LunaTerminal for market research
Data: Yahoo Finance via Fear & Greed (feargreedflow.com); 13F holdings from SEC filings. Market data can be delayed; check dates before relying on a figure. Answers are research, not financial advice.